Description of the immune microenvironment of chondrosarcoma and contribution to progression - Archive ouverte HAL Access content directly
Journal Articles OncoImmunology Year : 2017

Description of the immune microenvironment of chondrosarcoma and contribution to progression

(1) , (1) , , , , (1) , (2) , (1)
1
2

Abstract

Chondrosarcoma (CHS) is a rare bone malignancy characterized by its resistance to conventional systemic and radiation therapies. Whether immunotherapy targeting immune checkpoints may be active in these tumors remains unknown. To explore the role of the immune system in this tumor, we analyzed the immune environment of chondrosarcomas both in human sample, and in a syngeneic rat model, and tested the contribution of T lymphocytes and macrophages in chondrosarcoma progression. Immunohistochemical stainings were performed on human chondrosarcoma samples and on Swarm rat chondrosarcoma (SRC) model. Selective immunodepletion assays were performed in SRC to evaluate immune population's involvement in tumor progression. In human and rat chondrosarcoma, immune infiltrates composed of lymphocytes and macrophages were identified in the peritumoral area. Immune infiltrates composition was found correlated with tumors characteristics and evolution (grade, invasiveness and size). In SRC, selective depletion of T lymphocytes resulted in an accelerated growth rates, whereas depletion of CD163+ macrophages slowed down tumor progression. Splenocytes isolated from CHS-bearing SRC showed a specific cytotoxicity directed against chondrosarcoma cells (27%), which significantly decreased in CD3-depleted SRC (11%). The immune environment contributes to CHS progression in both human and animal models, suggesting that immunomodulatory approaches could be tested in bone chondrosarcoma

Dates and versions

hal-01795707 , version 1 (18-05-2018)

Identifiers

Cite

François A. Simard, Iseulys Richert, A. Vandermoeten, A.V. Decouvelaere, J.P. Michot, et al.. Description of the immune microenvironment of chondrosarcoma and contribution to progression. OncoImmunology, 2017, 6, pp.e1265716. ⟨10.1080/2162402X.2016.1265716⟩. ⟨hal-01795707⟩
27 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More